Drug Profile
Atorvastatin/S-metoprolol/ramipril - Emcure Pharmaceuticals
Alternative Names: Atorvastatin/ramipril/S-metoprolol; Metpure AR; Ramipril/atorvastatin/S-metoprolol; Ramipril/S-metoprolol/atorvastatin; S-metoprolol/atorvastatin/ramipril; S-metoprolol/ramipril/atorvastatinLatest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Emcure Pharmaceuticals
- Class Antihyperlipidaemics; Antihypertensives; Antimigraines; Class II antiarrhythmics; Fatty acids; Heart failure therapies; Heptanoic acids; Heterocyclic bicyclo compounds; Propanolamines; Pyrroles; Small molecules
- Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Essential hypertension; Hypercholesterolaemia
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-III for Essential hypertension (Treatment-naive) in India (PO)
- 07 Feb 2019 Chemical structure information added
- 09 Oct 2015 No recent reports on development identified - Phase-III for Essential hypertension (Treatment-naive) in India (PO)